Prospective Randomized Comparison of Sentinel Lymph Node Mapping Using Indocyanine Green and Conventional Pelvic Lymph Node Dissection in Clinical Stage I-II Endometrial Cancer
Through this clinical trial, the investigators aim to verify the usefulness and stability of sentinel lymph node mapping in endometrial cancer of clinical stage I-II.
⁃ 20 \
• 80 years old female
⁃ histologically diagnosed endometrial cancer that has never been treated before.
⁃ histological type :endometrioid, mucinous, serous, clear cell, uindifferentiated, dedifferentiated, mesonephric adenocarcinoma, mesonephric-like adenocarcinoma, carcinosarcoma, and mixed type
⁃ histological grade : FIGO grade 1, 2, 3
⁃ Presumed FIGO stage I-II
⁃ Planed for laparoscopic or robotic hystererctomy and lymph adenectomy
⁃ Largest pelvic or para-aortic lymph node diameter = or \< 15 mm in short axis on MRI
⁃ ECOG performance status 0-2
⁃ ASA PS 0-2
‣ WBC ≥ 3,000/mm3, Platelets ≥ 100,000/mm3, Creatinine ≤ 2.0 mg/dL ,Bilirubin ≤ 1.5 x institutional upper limit normal ,SGOT, SGPT, and ALP ≤ 3 x institutional upper limit normal
‣ A patient who voluntarily signed a document for the study.